British Association for Pyschopharmacology. To advance education and research in the science of psychopharmacology
President-elect until 2012; President until 2014; Past-President until 2016
Barbara Sahakian is a Professor at The University of Cambridge Department of
Psychiatry and MRC/Wellcome Trust Behavioural and Clinical Neuroscience Institute,
where she directs a laboratory of human psychopharmacology. She has an international
reputation in the field of psychopharmacology and related disciplines with over
16000 citations to her published work and an H index of 73. She is perhaps best
known for her work on cognitive enhancement using pharmacological treatments,
early detection of Alzheimer's disease, cognition and depression and neuroethics.
She was one of the first researchers to suggest that attentional dysfunction
in Alzheimer's disease could be ameliorated using pharmacotherapy, such as cholinesterase
inhibitors. She has over 300 publications covering these topics in scientific
journals, including Science, Nature, Nature Neuroscience, Annual Reviews of
Neuroscience, Archives of General Psychiatry, Biological Psychiatry, Psychological
Medicine, Journal of Psychopharmacology, Psychopharmacology, Neuropsychopharmacology,
International Journal of Neuropsychopharmacology and Neuroscience and Biobehavioural
Reviews. She is also on the Editorial Board of several of these journals. In
terms of peer esteem, she has been a member of the Medical Research Council
Neurosciences and Mental Health Board (2006 - 2010), a member of the Science
Coordination Team for the UK Government Foresight Project on Mental Capital
and Wellbeing (2008) and a member of the Society for Neuroscience (SfN) Committee
on Women in Neuroscience. She has just been appointed to the Scientific Advisory
Board for Grand Challenges in Global Mental Health. She has been given a number
of honours, including the FC Donders Chair in Psychopharmacology (Utrecht University,
2005), Fellow of the Academy of Medical Sciences (2004 - ), Distinguished International
Scholars Award (University of Pennsylvania, 2009 - 2010), Plenary lectures at
the Annual Meetings of ECNP (Barcelona, 2008) and CINP (Hong Kong, 2010) and
a Lecture for the President's Teaching Day at ACNP.
She has been a member of BAP Council and has been a regular contributor to BAP through organizing, chairing and speaking in Symposia and Workshops at the Annual Meetings. She has a strong interest in training young psychopharmacologists and a number of her current and previous PhD students are also members of BAP and participate in BAP events. She is committed to a translational approach to neuropsychopharmacology. Indeed, her current programme of research funded by the Wellcome Trust and Medical Research Council investigates the neurochemical modulation of impulsive and compulsive disorders, such as attention deficit hyperactivity disorder and obsessive compulsive disorder, using a translational medicine approach. She has extensively promoted the engagement of the public in science through communication with the media and participation in science festivals and many public lectures. As President of BAP, she would endeavour to preserve the excitement and stimulation of the annual meetings whilst encouraging training and career development of members and promoting Psychopharmacology through engagement with key stakeholders, including Industry, Government and Society.
Declaration of Interests
Have you, in the past three years, had patent/s or invention/s from which you may derive personal benefit in the area of psychopharmacology?
Have you, in the past three years, had ownership or part ownership of a company with interests in the area of psychopharmacology? (This would include holding the shares of major companies in oneís own name, or those of dependent family members.)
Shares in CeNeS, share options in Cambridge Cognition
Have you, in the past three years, accepted a personal retainer from any company with an interest in psychopharmacology?
Have you, in the past three years, acted as a consultant to any company with an interest in psychopharmacology?
Lundbeck, Servier and Cambridge Cognition
Have you, in the past three years, acted as an expert witness, either friendly or hostile, to any company with an interest in psychopharmacology?
Have you, in the past three years, held a research grant from any company with an interest in psychopharmacology?
Have you, in the past three years, had membership of the speakersí bureau for any company?
Have you, in the past three years, accepted paid speaking engagements in industry supported symposia?
Have you, in the past three years, accepted travel or hospitality NOT related to a speaking engagement?
Have you, in the past three years, recruited patients for industry-sponsored studies?
Form completed on 19 November 2013
Subscribe to the News Feed